ATE479425T1 - Sialsäure-derivate enthaltende feste dispersion - Google Patents

Sialsäure-derivate enthaltende feste dispersion

Info

Publication number
ATE479425T1
ATE479425T1 AT99916044T AT99916044T ATE479425T1 AT E479425 T1 ATE479425 T1 AT E479425T1 AT 99916044 T AT99916044 T AT 99916044T AT 99916044 T AT99916044 T AT 99916044T AT E479425 T1 ATE479425 T1 AT E479425T1
Authority
AT
Austria
Prior art keywords
solid dispersion
acid derivatives
dispersion containing
alpha
alkyl group
Prior art date
Application number
AT99916044T
Other languages
English (en)
Inventor
Takeshi Inamori
Chikako Takahashi
Yoshiyuki Fujimura
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE479425T1 publication Critical patent/ATE479425T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J15/00Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Colloid Chemistry (AREA)
AT99916044T 1998-04-10 1999-04-09 Sialsäure-derivate enthaltende feste dispersion ATE479425T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9889998 1998-04-10
PCT/JP1999/001907 WO1999052931A1 (fr) 1998-04-10 1999-04-09 Dispersion solide contenant un derive d'acide sialique

Publications (1)

Publication Number Publication Date
ATE479425T1 true ATE479425T1 (de) 2010-09-15

Family

ID=14231987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916044T ATE479425T1 (de) 1998-04-10 1999-04-09 Sialsäure-derivate enthaltende feste dispersion

Country Status (10)

Country Link
US (1) US6444649B1 (de)
EP (1) EP1070725B9 (de)
JP (1) JP4427900B2 (de)
KR (1) KR100525275B1 (de)
CN (1) CN1183154C (de)
AT (1) ATE479425T1 (de)
CA (1) CA2328085C (de)
DE (1) DE69942721D1 (de)
HK (1) HK1038023A1 (de)
WO (1) WO1999052931A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009123877A1 (en) * 2008-03-21 2009-10-08 Braincells, Inc. A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
US9119866B2 (en) 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
EP2116139A1 (de) * 2008-05-08 2009-11-11 Nestec S.A. Sialisäure zur Stärkung der Gehirngesundheit bei älteren Menschen
US9241896B2 (en) * 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
CA2805222A1 (en) 2010-07-13 2012-01-19 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
WO2013012959A1 (en) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
BR112014009760B1 (pt) 2011-10-24 2022-11-29 Ultragenyx Pharmaceutical Inc Análogos de ácido siálico, seu uso e composição farmacêutica
EP4066841A1 (de) 2013-03-14 2022-10-05 University of Maryland, Baltimore Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2017048817A1 (en) 2015-09-14 2017-03-23 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
CN110577557B (zh) * 2018-06-08 2022-03-11 沈阳药科大学 唾液酸脂质衍生物及其制备方法和应用
CN110478324B (zh) * 2019-08-27 2022-02-08 嘉必优生物技术(武汉)股份有限公司 一种唾液酸微粒及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229441A (en) 1978-12-01 1980-10-21 Merck & Co., Inc. Immunologic adjuvant
JPS5877811A (ja) 1981-11-04 1983-05-11 Kanebo Ltd 安定な易吸収性ニフエジピン製剤の製法
JPH064671B2 (ja) 1985-04-02 1994-01-19 メクト株式会社 シアル酸誘導体及びその製造方法
JPH0631291B2 (ja) 1985-06-07 1994-04-27 第一製薬株式会社 S−ノイラミン酸誘導体
JPS62209094A (ja) * 1986-03-10 1987-09-14 Nippon Zoki Pharmaceut Co Ltd 新規シアル酸誘導体及びその製造方法
JPH0696535B2 (ja) 1986-05-12 1994-11-30 メクト株式会社 シアロシルコレステロ−ルの神経障害疾患治療剤
JPH07116216B2 (ja) * 1986-09-04 1995-12-13 メクト株式会社 シアロシルコレステロ−ルの製造方法
CA1324603C (en) * 1986-05-12 1993-11-23 Haruo Ogura Sialosyl cholesterol, process for producing the same, and neuropathy remedy comprising the same
JPH07116206B2 (ja) 1986-08-08 1995-12-13 和光純薬工業株式会社 新規なシアル酸誘導体
JPH0714952B2 (ja) 1986-08-08 1995-02-22 和光純薬工業株式会社 シアル酸誘導体
JPS6368526A (ja) 1986-09-11 1988-03-28 Mect Corp シアリルグリセライドからなる神経障害疾患治療剤
JPS6452794A (en) 1987-05-29 1989-02-28 Kanto Ishi Pharma Co Ltd Sialic acid-containing thioglycerolipid derivative and production thereof
JPH0193529A (ja) 1987-10-05 1989-04-12 Mect Corp シアロシルコレステロールの脱髄性疾患治療剤
JP2729201B2 (ja) 1988-01-21 1998-03-18 メクト株式会社 アミド結合を持ったシアル酸誘導体
JPH0377898A (ja) 1989-08-17 1991-04-03 Mect Corp シアロシルコレステロールからなる筋ジストロフィー症治療剤
JP2793279B2 (ja) 1989-08-22 1998-09-03 メクト株式会社 シアロシルコレステロールを含有する抗痴呆薬
JPH03151398A (ja) 1989-11-06 1991-06-27 Mect Corp シアル酸結合生理活性ペプチド及びその製造方法
JPH07504884A (ja) 1991-11-11 1995-06-01 シムビコム アクティボラーグ ガングリオシド類似体
IT1260156B (it) 1992-08-03 1996-03-28 Fidia Spa Derivati dell'acido neuraminico
JP3778372B2 (ja) 1993-12-24 2006-05-24 三菱化学株式会社 シアル酸誘導体
DE4445580C1 (de) 1994-12-20 1995-12-21 Daimler Benz Ag Hardtop-Fahrzeug
JPH092957A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 末梢性神経障害の治療、予防薬

Also Published As

Publication number Publication date
CA2328085A1 (en) 1999-10-21
JP4427900B2 (ja) 2010-03-10
US6444649B1 (en) 2002-09-03
CN1183154C (zh) 2005-01-05
KR100525275B1 (ko) 2005-11-02
KR20010042603A (ko) 2001-05-25
EP1070725A4 (de) 2008-12-31
EP1070725A1 (de) 2001-01-24
EP1070725B9 (de) 2011-02-23
CN1305489A (zh) 2001-07-25
WO1999052931A1 (fr) 1999-10-21
HK1038023A1 (en) 2002-03-01
EP1070725B1 (de) 2010-09-01
CA2328085C (en) 2006-08-22
DE69942721D1 (de) 2010-10-14

Similar Documents

Publication Publication Date Title
ATE479425T1 (de) Sialsäure-derivate enthaltende feste dispersion
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
DE69628276D1 (de) Zubereitung von xanthinderivaten als feste dispersion
AU569983B2 (en) Xanthine derivatives
EA200200374A1 (ru) Производные хинолилпропилпиперидина, их получение и содержащие их композиции
EP0945452A4 (de) Zuckerderivate, geliermittel, geliermittelzubereitungen, verfahren zu ihrer herstellung und gelzubereitungen
SG44794A1 (en) Novel peptide derivatives
CA2325045A1 (en) Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
TR200201072T2 (tr) 4-Triflorometilsulfinilpirazol türevi hazırlama süreci
TR200100609T1 (tr) Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik
ATE255579T1 (de) Pyrrolidin-derivate die eine phospholipase-a2- hemmende wirkung haben
WO2002024623A3 (en) Novel alkanoic acid derivatives
AU2044697A (en) Phenylalkylcarboxylic acid derivatives
AU3784597A (en) Fat emulsion containing xanthine derivative
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
AU5197599A (en) Fluorescent labelling reagents
EP0497001A3 (en) Oxidized-type glutathione alkyl ester
ES2186191T3 (es) Productos de reaccion del acido fosfonico y su uso en composiciones de recubrimiento.
AU2005400A (en) Remedies
AU2408602A (en) Indole derivatives and use thereof in medicines
FI913658A0 (fi) 4-amino-d4,6-steroider och deras anvaendning som 5a-reduktas-inhibitorer.
HU9203849D0 (en) Thiazole derivatives
AU2651597A (en) Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient
AU5715894A (en) Methotrexate derivative

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties